NO20084380L - Neuromedin U-reseptoragonister og anvendelser derav - Google Patents
Neuromedin U-reseptoragonister og anvendelser deravInfo
- Publication number
- NO20084380L NO20084380L NO20084380A NO20084380A NO20084380L NO 20084380 L NO20084380 L NO 20084380L NO 20084380 A NO20084380 A NO 20084380A NO 20084380 A NO20084380 A NO 20084380A NO 20084380 L NO20084380 L NO 20084380L
- Authority
- NO
- Norway
- Prior art keywords
- neuromedin
- receptor agonists
- applications
- obesity
- diabetes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
- C07K14/43—Sweetening agents, e.g. thaumatin, monellin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Botany (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Sammendrag Neuromedin U-reseptoragonister for anvendelse ved behandlingen av metabolske forstyrrelser slik som fedme og diabetes, er beskrevet.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78393306P | 2006-03-20 | 2006-03-20 | |
PCT/US2007/006635 WO2007109135A2 (en) | 2006-03-20 | 2007-03-16 | Neuromedin u receptor agonists and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20084380L true NO20084380L (no) | 2008-12-16 |
Family
ID=38522976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20084380A NO20084380L (no) | 2006-03-20 | 2008-10-17 | Neuromedin U-reseptoragonister og anvendelser derav |
Country Status (15)
Country | Link |
---|---|
US (2) | US20070244048A1 (no) |
EP (1) | EP1999143B1 (no) |
JP (1) | JP2009530379A (no) |
KR (1) | KR20090005329A (no) |
CN (1) | CN101443356A (no) |
AT (1) | ATE516300T1 (no) |
AU (1) | AU2007227510A1 (no) |
BR (1) | BRPI0708943A2 (no) |
CA (1) | CA2647027A1 (no) |
IL (1) | IL193996A0 (no) |
MX (1) | MX2008012055A (no) |
NO (1) | NO20084380L (no) |
RU (1) | RU2008141280A (no) |
WO (1) | WO2007109135A2 (no) |
ZA (1) | ZA200807789B (no) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1577323B1 (en) | 2002-12-26 | 2013-07-10 | Takeda Pharmaceutical Company Limited | Metastin derivative and use thereof |
AU2005257484A1 (en) | 2004-06-25 | 2006-01-05 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
US8404643B2 (en) | 2005-12-22 | 2013-03-26 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
TWI404726B (zh) | 2006-10-25 | 2013-08-11 | Takeda Pharmaceutical | 腫瘤轉移抑制素衍生物及其用途 |
US8309522B2 (en) | 2007-02-05 | 2012-11-13 | Amylin Pharmaceuticals, Llc | Neuromedin and FN-38 peptides for treating psychiatric diseases |
JP2010539059A (ja) * | 2007-09-11 | 2010-12-16 | モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト | 例えばAIDSまたはアルツハイマーの治療のための治療剤としてのβ−メラノトロピンの使用 |
WO2009044918A1 (ja) * | 2007-10-05 | 2009-04-09 | Takeda Pharmaceutical Company Limited | ニューロメジンu誘導体 |
US20090104210A1 (en) * | 2007-10-17 | 2009-04-23 | Tota Michael R | Peptide compounds for treating obesity and insulin resistance |
PL2314609T3 (pl) * | 2008-07-30 | 2017-07-31 | Takeda Pharmaceutical Company Limited | Pochodne metastyny i ich zastosowanie |
JP2012507558A (ja) * | 2008-11-05 | 2012-03-29 | メルク・シャープ・エンド・ドーム・コーポレイション | ニューロメジンuの作用メカニズムおよびその用途 |
JO2870B1 (en) | 2008-11-13 | 2015-03-15 | ميرك شارب اند دوهم كورب | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes |
WO2010067233A1 (en) | 2008-12-08 | 2010-06-17 | Pfizer Inc. | 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir) |
EP2418213B1 (en) * | 2009-04-08 | 2014-11-19 | Takeda Pharmaceutical Company Limited | Neuromedin u derivative |
WO2010138343A1 (en) * | 2009-05-27 | 2010-12-02 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists |
WO2011005611A1 (en) * | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
EP2473047B1 (en) | 2009-09-02 | 2014-08-13 | Merck Sharp & Dohme Corp. | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
US20110105389A1 (en) * | 2009-10-30 | 2011-05-05 | Hoveyda Hamid R | Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same |
WO2011051916A2 (en) * | 2009-11-02 | 2011-05-05 | Universite De Geneve | Stabilized protein formulations and use thereof |
EP2538783B1 (en) | 2010-02-22 | 2016-06-01 | Merck Sharp & Dohme Corp. | Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
US8980929B2 (en) | 2010-05-21 | 2015-03-17 | Merck Sharp & Dohme Corp. | Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
JP2013209295A (ja) | 2010-10-13 | 2013-10-10 | Takeda Chem Ind Ltd | ペプチド誘導体 |
WO2012106581A1 (en) * | 2011-02-03 | 2012-08-09 | The University Of Chicago | Fxr inhibitor, bile acid sequestrant as combination therapy for cholesterol reduction |
CN104411710A (zh) | 2012-04-16 | 2015-03-11 | 卡内克制药公司 | 作为ptp-1b抑制剂前体的稠合的芳族膦酸酯衍生物 |
EP2842965A1 (en) | 2013-09-03 | 2015-03-04 | Gubra ApS | Neuromedin U analogs comprising serum albumin binding amino acid residue |
ES2927607T3 (es) * | 2013-09-13 | 2022-11-08 | Scripps Research Inst | Agentes terapéuticos modificados y composiciones de los mismos |
EP4212180A1 (en) | 2013-12-18 | 2023-07-19 | The Scripps Research Institute | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
CN110183514B (zh) * | 2016-04-21 | 2022-12-30 | 上海天慈生命科学发展有限公司 | 一类阿片和神经肽ff受体的多靶点肽类分子及其制备和应用 |
AU2017378378A1 (en) | 2016-12-13 | 2019-07-04 | Limm Therapeutics, SA | Methods of treating diseases associated with ILC2 cells |
JP7201967B2 (ja) * | 2017-01-20 | 2023-01-11 | 学校法人東京薬科大学 | ペプチドもしくはその薬学的に許容される塩、またはそれらのプロドラッグ |
JP7181550B2 (ja) * | 2017-01-20 | 2022-12-01 | 学校法人東京薬科大学 | ペプチド、その薬学的に許容される塩、またはそれらのプロドラッグ、およびそれらの用途 |
US20240279278A1 (en) | 2023-01-12 | 2024-08-22 | Boehringer Ingelheim International Gmbh | Nmu receptor 2 agonists |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1237001A4 (en) * | 1999-11-29 | 2005-03-23 | Takeda Pharmaceutical | SCREENING PROCEDURES |
-
2007
- 2007-03-16 KR KR1020087025492A patent/KR20090005329A/ko not_active Application Discontinuation
- 2007-03-16 US US11/724,846 patent/US20070244048A1/en not_active Abandoned
- 2007-03-16 JP JP2009501467A patent/JP2009530379A/ja not_active Withdrawn
- 2007-03-16 EP EP07753276A patent/EP1999143B1/en not_active Not-in-force
- 2007-03-16 CN CNA2007800174124A patent/CN101443356A/zh active Pending
- 2007-03-16 RU RU2008141280/04A patent/RU2008141280A/ru not_active Application Discontinuation
- 2007-03-16 WO PCT/US2007/006635 patent/WO2007109135A2/en active Application Filing
- 2007-03-16 AT AT07753276T patent/ATE516300T1/de not_active IP Right Cessation
- 2007-03-16 AU AU2007227510A patent/AU2007227510A1/en not_active Abandoned
- 2007-03-16 MX MX2008012055A patent/MX2008012055A/es unknown
- 2007-03-16 CA CA002647027A patent/CA2647027A1/en not_active Abandoned
- 2007-03-16 BR BRPI0708943-0A patent/BRPI0708943A2/pt not_active IP Right Cessation
-
2008
- 2008-09-09 IL IL193996A patent/IL193996A0/en unknown
- 2008-09-10 ZA ZA200807789A patent/ZA200807789B/xx unknown
- 2008-10-17 NO NO20084380A patent/NO20084380L/no not_active Application Discontinuation
-
2009
- 2009-11-20 US US12/623,085 patent/US20100075907A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2007227510A1 (en) | 2007-09-27 |
WO2007109135A3 (en) | 2008-04-03 |
JP2009530379A (ja) | 2009-08-27 |
WO2007109135A2 (en) | 2007-09-27 |
EP1999143A2 (en) | 2008-12-10 |
ZA200807789B (en) | 2009-12-30 |
RU2008141280A (ru) | 2010-04-27 |
US20100075907A1 (en) | 2010-03-25 |
ATE516300T1 (de) | 2011-07-15 |
BRPI0708943A2 (pt) | 2011-06-14 |
IL193996A0 (en) | 2011-08-01 |
US20070244048A1 (en) | 2007-10-18 |
MX2008012055A (es) | 2008-10-02 |
CN101443356A (zh) | 2009-05-27 |
KR20090005329A (ko) | 2009-01-13 |
CA2647027A1 (en) | 2007-09-27 |
EP1999143B1 (en) | 2011-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20084380L (no) | Neuromedin U-reseptoragonister og anvendelser derav | |
DK2367793T3 (da) | GPR120-receptoragonister og anvendelser deraf. | |
AU2007221366A8 (en) | Oxyntomodulin derivatives | |
CL2008002042A1 (es) | Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos. | |
BRPI0915282A2 (pt) | agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade | |
NO20091734L (no) | Glucagonreseptorantagonistforbindelser, preparater inneholdende slike forbindelser, og metoder for anvendelse | |
NO20080010L (no) | GPCR-agonister | |
EP1993560A4 (en) | CANNABINOID RECEPTOR ANTAGONISTS / INVERSE AGONISTS TO TREAT OVERWEIGHT | |
MY160773A (en) | Oxyntomodulin peptide analogue | |
GB2465677B (en) | Non-systemic delivery of satiogens for use in the treatment of obesity and/or diabetes | |
EA200900796A1 (ru) | Пиперидиновые агонисты gpcr | |
NO20092034L (no) | Kjemiske forbindelser og anvendelser | |
EA200900880A1 (ru) | Пиперидиновые агонисты gpcr | |
CL2008003847A1 (es) | Compuestos derivados de 6-fenilpirazin-2-carboxamida y 6-fenilpirazin-2-carbotioamida, inhibidores de dgat-1; composicion farmaceutica; y su uso en el tratamiento de la diabetes mellitus y obesidad. | |
DK2170930T3 (da) | Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme | |
TW200608961A (en) | Methods and reagents for the treatment of metabolic disorders | |
NO20091700L (no) | Florizinanaloger som inhibitorer av glukose-ko-transporter 2 | |
DK2185164T3 (da) | Sammensætning og terapeutisk antitumorvaccine | |
EA200802184A1 (ru) | Фармацевтические композиции с ингибиторами dpp iv | |
DK2069352T3 (da) | Bestemte kemiske enheder, sammensætninger og fremgangsmåder | |
MX2009011359A (es) | Derivados de pirimidinona y sus metodos de uso. | |
DK2077976T3 (da) | Bioaktiv, rutheniumholdig belægning og indretning | |
DK1901731T3 (da) | Niacinreceptoragonister, sammensætninger indeholdende sådanne forbindelser og fremgangsmåder til behandling | |
EA200900878A1 (ru) | Пиперидиновые агонисты gpcr | |
TN2012000002A1 (en) | Gpr119 agonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |